ZEPP
INSIDER SELLZepp Health Corp
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeZepp Health posted modest 6.9% YoY revenue growth in Q2 2026 but saw adjusted operating losses widen significantly to $11.1M, driven by elevated marketing and launch spending. Q3 2026 guidance projects a year-over-year revenue decline against a high 78.5% YoY comparison base, with analyst downgrades to 'sell' and insider selling signaling deteriorating investor confidence despite new premium product launches.
Red flags
- •Q3 2026 revenue guidance of $68.0M–$73.0M represents a decline vs. Q3 2025's $75.8M (high comparison base creates sequential headwind)
- •Adjusted operating loss widened >$6M YoY in Q2 2026 despite only 6.9% revenue growth, indicating margin compression and loss of operational leverage
- •Dual downgrade to 'sell' by Wall Street Zen (July and September 2026) amid worsening profitability outlook
- •Stock trading near 52-week lows (~$4) and below 200-day moving average as of late September 2026
- •Insider selling by executive Pengtao Yu in late September 2026 at depressed price levels
- •Gross margin improvement (36.2% to 37.4%) insufficient to offset 68% operating expense increase, signaling profitability challenged by high marketing spend
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).